Pancreatic Cancer Research

ResearcherNo recent work listed

Johanna C. Bendell

ORCID-verified (high confidence)As of 9 November 2026

Matched on ORCID iD 0000-0001-9426-5891; OpenAlex author ID A5028472820, A5088613691.

Their work

Papers
13 (first author 2, last author 1)
Trials
2
Grants
0
Collaborators
65
Papers, trials and grants by year

2013: 1 trial · 2014: none · 2015: 2 papers, 1 trial · 2016: none · 2017: 3 papers · 2018: 1 paper · 2019: 1 paper · 2020: 4 papers · 2021: 2 papers

Papers 13

  1. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1007/s10637-020-01000-6↗
  2. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gem… Co-author DOI 10.1200/jco.20.02232↗
  3. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine i… Co-author DOI 10.1016/j.annonc.2019.09.004↗
  4. Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel a… Co-author DOI 10.1016/j.annonc.2020.05.011↗
  5. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing… Co-author DOI 10.1186/s12885-020-07110-x↗
  6. Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I … First author DOI 10.1634/theoncologist.2020-0474↗
  7. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1002/cam4.2425↗
  8. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase… Co-author DOI 10.1007/s10637-018-0580-2↗
  9. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing … Co-author DOI 10.1007/s10637-017-0473-9↗
  10. A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreat… Co-author DOI 10.1634/theoncologist.2017-0024↗
  11. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAI… Last author DOI 10.1634/theoncologist.2017-0066↗
  12. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/meta… First author DOI 10.1093/annonc/mdu581↗
  13. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Ther… Co-author DOI 10.1200/jco.2015.61.4578↗

Trials 2

  1. TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors Study chair NCT02574663↗
  2. Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer Study chair NCT01844817↗

Closest collaborators

The 25 strongest of 65 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

  1. Zev A. Wainberg · 5 shared papers, 2015–2021
  2. Joel Randolph Hecht · 4 shared papers, 2017–2021
  3. Andrew H. Ko · 3 shared papers, 2017–2020
  4. Teresa Mercade Macarulla · 3 shared papers, 2017–2021
  5. J. Marc Pipas · 3 shared papers, 2015–2020
  6. Andrés Jesús Muñoz Martín · 2 shared papers, 2020–2021
  7. Sara Lonardi · 2 shared papers, 2020–2021
  8. Baek-Yeol Ryoo · 2 shared papers, 2020–2021
  9. Manish R. Patel · 2 shared papers, 2020–2021
  10. Eileen Mary O'Reilly · 3 shared papers, 2015–2019
  11. Syed Farhan Zafar · 2 shared papers, 2020
  12. Fernando Rivera Herrero · 2 shared papers, 2020
  13. David J. Watkins · 2 shared papers, 2020
  14. Uwe Pelzer · 2 shared papers, 2020
  15. Hana Algül · 2 shared papers, 2020
  16. Madappa N. Kundranda · 2 shared papers, 2020
  17. Eric Van Cutsem · 2 shared papers, 2018–2021
  18. Vaibhav Sahai · 2 shared papers, 2018–2019
  19. Kenneth H. Yu · 2 shared papers, 2018–2019
  20. Ivelina Gueorguieva · 1 shared paper, 2021
  21. Joon Oh Park · 1 shared paper, 2021
  22. Richard Greil · 1 shared paper, 2021
  23. Charles D. Lopez · 1 shared paper, 2021
  24. Herbert I. Hurwitz · 2 shared papers, 2015–2018
  25. Myung Ah Lee · 1 shared paper, 2020

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.